AAA March 2018 – Page 20

Inscripta details series C funding

US-based gene-editing technology developer Inscripta closed a $55.5m series C round on Wednesday co-led by Mérieux Développement, the investment arm of healthcare technology provider Institut Mérieux. Venture capital firm Paladin Capital co-led the round, which also featured Venrock, Foresite, MLS Capital and NanoDimension. Founded in 2015 as Muse Biotechnology, Inscripta’s offering enables researchers to engineer… Continue reading Inscripta details series C funding